Navigation

🏠 Home 📰 Latest News 🌍 World 🇮🇳 India 💼 Business 💻 Technology ⚽ Sports 🎬 Entertainment 🏥 Health
Biggest News Aggregation in the World
📰 Inflammatory Phenotype News

Inflammatory Phenotype News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Inflammatory Phenotype. Real-time updates on events, politics, business and more.

Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

June 5, 2023
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% (hazard ratio of 0.29) compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel
United States Comunidad Autonoma De Cataluna Mecklenburg Vorpommern Bruxelles Capitale Timothy Mccarthy Aleix Prat
Source: finanznachrichten.de

Oncolytics Biotech® Announces Updated Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial that Show Pelareorep Driving Robust Increases in Progression-Free Survival and Confirmed Overall Response Rate

June 5, 2023
Pelareorep-paclitaxel combination reduced risk of disease progression by 71% compared to paclitaxel monotherapy 37.5% confirmed overall response rate with pelareorep-paclitaxel vs. 13.3% with... | June 5, 2023
United States Bruxelles Capitale Comunidad Autonoma De Cataluna Oncolytic Reovirus Pelareorep Matt Coffey Aleix Prat
Source: marketscreener.com

Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives =50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

May 25, 2023
31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off
United States Oncolytic Reovirus Pelareorep Jon Patton Timothy Mccarthy Matt Coffey Thomas Heineman
Source: finanznachrichten.de

Oncolytics Biotech® Announces Positive Randomized Phase 2 Data from BRACELET-1 Metastatic Breast Cancer Trial Demonstrating Pelareorep Drives ≥50% Improvements in ORR and mPFS in an ASCO Annual Meeting Abstract

May 25, 2023
31% week-16 overall response rate and 9.6-month median progression-free survival with pelareorep plus paclitaxel vs. 20% and 6.4 months with paclitaxel alone as of Oct. 2022 ASCO abstract cut-off... | June 11, 2023
United States Oncolytic Reovirus Pelareorep Thomas Heineman Jon Patton Timothy Mccarthy Matt Coffey
Source: marketscreener.com

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Oncolytics Biotech® Inc.: Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting

April 26, 2023
Oral presentation on BRACELET-1 to take place on June 3, 2023 SAN DIEGO and CALGARY, AB, April 26, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced
United States Jon Patton Oncolytic Reovirus Pelareorep Timothy Mccarthy Matt Coffey American Society Of Clinical Oncology
Source: finanznachrichten.de

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science